Breaking Down Bristol-Myers Squibb Company Ce Financial Health: Key Insights for Investors

Investors scrutinizing Bristol-Myers Squibb's financial pulse will want to dig into headline figures like Q3 2025 revenue of $12.2 billion (up 3% YoY) despite a 59% slump in Revlimid sales, the 18% year-over-year surge in the Growth Portfolio that powered a raised full-year revenue guidance to $47.5-48 billion, and performance offsets such as EBITDA of $2.2 billion alongside Non-GAAP diluted EPS of $1.63 (down 9%); beneath those signals sit mixed profitability and valuation cues-from a gross margin decline to 72.9%, an Altman Z-Score of 1.79 flagging distress-zone risk, a 2.92 debt-to-equity stance tempered by $6.4 billion of net-debt reduction year-to-date, and market multiples (P/E 18.4, forward P/E 7.56, P/S 1.96) that suggest potential upside for selective investors-read on for the detailed breakdown, ratios, risks, and catalysts that matter for portfolio decisions.

Bristol-Myers Squibb Company Ce (CELG-RI) Revenue Analysis

• Q3 2025 total revenue: $12.2 billion (+3% YoY)
• Revlimid: -59% YoY (impacting the Legacy Portfolio)
• Growth Portfolio: +18% YoY
• Eliquis: +25% worldwide sales growth
• Legacy Portfolio YTD revenue: $11.31 billion (-17% YTD)
• U.S. gross-to-net adjustment: increased by 6 percentage points YTD to 52%
• Full-year revenue guidance raised to $47.5-48.0 billion

• Growth Portfolio momentum - products such as Camzyos and Breyanzi drove the 18% growth, offsetting part of Revlimid declines.
• Product concentration - Eliquis's 25% growth provided a significant buffer against the Legacy Portfolio contraction.
• Payer dynamics - the U.S. gross-to-net increase to 52% (up 6 pts) reflects higher government channel rebates and Medicare Part D redesign impacts, reducing net realized revenue.
• Legacy erosion - the 17% year-to-date decline to $11.31 billion underscores ongoing post-patent challenges.

Bristol-Myers Squibb Company Ce (CELG-RI) Profitability Metrics

• Non-GAAP Diluted EPS: $1.63 in Q3 2025, down 9% year-over-year - driven by margin erosion and increased external pipeline investments.
• Non-GAAP Gross Margin: 72.9% in Q3 2025, a decline of 3.1 percentage points from 76.0% the prior year period.
• EBITDA: $2.2 billion in Q3 2025, up 86.99% versus Q3 2024, reflecting improved operating cash profitability and cost dynamics.
• EBITDA Margin: 18.34% in Q3 2025, a significant improvement from the previous quarter (quarterly comparison improvement noted by management).
• Return on Equity (ROE): 0.34% in Q3 2025, a 76% increase year-over-year - indicating improved returns to shareholders despite low absolute level.
• Return on Capital Employed (ROCE): -0.10% in Q3 2025, a 16% improvement year-over-year though still slightly negative, signaling ongoing capital deployment challenges.

• Drivers to watch: pipeline investment cadence, product mix shifts, pricing and gross margin recovery initiatives.
• Risk factors: continued margin compression could further depress EPS unless offset by higher sales or cost reductions.
• Positive signals: large YoY EBITDA growth and sequential EBITDA margin expansion point to stronger cash-generating ability.
• Investor focus: reconcile EPS weakness with EBITDA strength and monitor ROE/ROCE trends for evidence of sustainable capital returns.

Bristol-Myers Squibb Company Ce (CELG-RI) - Debt vs. Equity Structure

Bristol-Myers Squibb Company Ce (CELG-RI) shows a capital structure with a meaningful tilt toward debt financing historically, though recent quarters reflect active deleveraging and improved flexibility.

• Debt-to-Equity ratio most recently reported at 2.92 (prior-period figure used as a base for recent YoY comparison).
• Debt-to-Equity decreased by 8.97% to 2.63 in Q3 2025 versus the same quarter a year earlier.
• Net debt was reduced by $6.4 billion during the nine months ending September 2025.
• Five-year range: peak Debt-to-Equity of 3.36 in Q1 2024 and a low of 0.87 in Q4 2022.
• Debt-to-Equity rose 124.60% in 2024 compared with 2023, reflecting significant leverage build in that period before recent paydowns.
• Management has signaled and executed active debt management to improve financial flexibility.

Key implications for investors:

• Leverage profile remains above 1.0, indicating material debt load versus equity but trending lower after recent reductions.
• Large net-debt paydown ($6.4B through Sep 2025) improves interest coverage prospects and liquidity headroom.
• Volatility in the ratio (0.87-3.36 over five years) underscores sensitivity to acquisitions, one-time items, and capital-return policies.
• Continued active debt management should be monitored alongside earnings, cash flow, and capital-allocation decisions.

For additional context on strategic alignment and long-term priorities, see Mission Statement, Vision, & Core Values (2026) of Bristol-Myers Squibb Company Ce.

Bristol-Myers Squibb Company Ce (CELG-RI) - Liquidity and Solvency

• Current ratio: 1.21 - adequate capacity to cover short-term liabilities.
• Quick ratio: 1.11 - sufficient immediately available assets to meet imminent obligations.
• Altman Z-Score: 1.79 - in the distress zone, indicating potential bankruptcy risk within the next two years if conditions deteriorate.
• Net debt trend: company has been reducing net debt, improving liquidity and flexibility.
• Debt-to-Equity (2024): increased by 124.60% year-over-year, signaling higher leverage in the most recent reporting period.
• Debt management: active measures to manage and refinance debt to improve financial flexibility.

Key implications for investors include monitoring cash-flow generation and interest coverage in upcoming quarters, watching management's net-debt trajectory, and tracking whether operating performance and asset sales or refinancing plans materially improve the Altman Z-Score and reduce leverage. For deeper investor context and holder activity, see: Exploring Bristol-Myers Squibb Company Ce Investor Profile: Who's Buying and Why?

Bristol-Myers Squibb Company Ce (CELG-RI) Valuation Analysis

• P/E ratio: 18.4 - current trailing multiple indicating reasonable earnings valuation.
• Forward P/E: 7.56 - market is pricing materially higher expected earnings, signaling potential upside if guidance is met.
• P/S ratio: 1.96 - near its 10-year low, implying revenue is being valued conservatively.
• P/B ratio: 5.32 - close to its 1-year low, supporting an undervaluation thesis on net-asset basis.
• Analyst sentiment: target price $51.63 and recommendation score 2.7 - moderately positive consensus.
• Beta: 0.7 - lower volatility than the broader market, attractive for risk-averse investors.
• Debt: active management measures in place to improve financial flexibility and reduce leverage risk.

Bristol-Myers Squibb Company Ce (CELG-RI) Risk Factors

• Altman Z-Score and financial distress: The company's Altman Z-Score sits around 1.5, which places it in the zone associated with heightened financial distress and warrants close monitoring of liquidity and solvency metrics.
• Patent cliff and Revlimid exposure: Revlimid (lenalidomide) represented one of the largest revenue drivers historically - peak annual sales near $9.7 billion - and generic erosion has created a material revenue gap the company must replace.
• Pipeline setbacks: Recent clinical trial failures for Cobenfy, Camzyos, and Reblozyl create downside risk to future sales and valuation assumptions embedded in forecasts.
• Leverage dynamics: Debt-to-Equity increased sharply in 2024 - a 124.60% rise versus the prior year - reflecting balance-sheet pressures despite active debt management efforts.
• Volatility profile: The stock's beta of approximately 0.7 implies lower volatility than the market, which may attract risk-averse investors but does not remove company-specific operational risks.

• Debt management: Management has been actively refinancing and extending maturities, using free cash flow and asset-light initiatives to improve financial flexibility and reduce near-term rollover risk.
• Revenue replacement strategies: The company is pursuing launches, label expansions, and M&A to offset Revlimid declines; effectiveness depends on successful commercialization and regulatory outcomes.
• Investor considerations: Lower beta reduces market-driven volatility exposure, but high leverage, a low Altman Z-Score, and pipeline uncertainty increase idiosyncratic risk - stress-test scenarios should account for persistent revenue shortfalls and higher interest costs.

Bristol-Myers Squibb Company Ce (CELG-RI) - Growth Opportunities

Bristol-Myers Squibb Company Ce (CELG-RI) is positioning its portfolio and balance sheet to capture mid- to long-term growth while managing near-term financial flexibility.

• Growth Portfolio expansion: reported 18% year-over-year revenue growth driven by newer launches including Camzyos and Breyanzi.
• Updated guidance: management raised full-year revenue guidance to $47.5-48.0 billion, signaling confidence in sustained top-line momentum.
• Product strength: Eliquis recorded 25% worldwide sales growth, providing a substantial cash-flow buffer against pressures on legacy assets.
• Strategic M&A: acquisitions such as Orbital Therapeutics target capabilities in cell therapy and RNA technology to diversify future revenue streams.
• Capital structure focus: active debt management efforts are underway to improve financial flexibility and support investment in growth areas.

• Investment emphasis: allocate capital to high-growth biologics and cell/RNA platforms while prioritizing deleveraging steps where appropriate.
• Operational levers: commercialization scale-ups for Camzyos and Breyanzi and sustained Eliquis demand are primary near-term growth drivers.
• Financial levers: debt reduction, targeted divestitures, or structured financing could be used to lower leverage and fund R&D/bolt-on acquisitions.

For additional corporate background and how the company creates value, see: Bristol-Myers Squibb Company Ce: History, Ownership, Mission, How It Works & Makes Money